TY - JOUR A1 - Feuerriegel, Uwe A1 - Hoffmann, Ulrich A1 - Walenzik, C. A1 - Kögel, J. T1 - Für Scale-up´s und Betriebsmuster, Projekt Trocknungstechnik an der FH Aachen JF - CITplus : das Praxismagazin für Verfahrenstechnik und Apparatebau. 4 (2001) Y1 - 2001 SN - 1436-2597 SP - 24 EP - 25 ER - TY - JOUR A1 - Mang, Thomas A1 - Roosen, C. A1 - Ansorge, M. A1 - Leitner, W. T1 - Gaining pH-control in water/carbon dioxide biphasic systems / Abstract No. 1038 / Roosen, Ch. ; Ansorge, M. ; Mang, Thomas ; Leitner, W. ; Greiner, L. JF - Green solvents for processes : Lake Constance, Friedrichshafen, Germany, 8 - 11 October 2006 ; book of abstracts / DECHEMA e.V. Y1 - 2006 N1 - DECHEMA, Gesellschaft für Chemische Technik und Biotechnologie ; [Conference] ; ((Friedrichshafen) : 2006.10.08-11) PB - DECHEMA CY - Frankfurt am Main ER - TY - JOUR A1 - Mang, Thomas A1 - Roosen, Christoph A1 - Ansorge-Schumacher, Marion A1 - Leitner, Walter T1 - Gaining pH-control in water/carbon dioxide biphasic systems / Roosen, Christoph ; Ansorge-Schumacher, Marion ; Mang, Thomas ; Leitner, Walter ; Greiner, Lasse JF - Green Chemistry. 9 (2007) Y1 - 2007 SN - 1463-9262 SP - 455 EP - 458 ER - TY - JOUR A1 - Scherer, Ulrich W. A1 - Gäggeler, H. W. A1 - Jost, D. T. A1 - Kovacs, J. T1 - Gas Phase Chromatography Experiments with Bromides of Tantalum and Element 105 / H.W. Gäggeler, D.T. Jost, J. Kovacs, U.W. Scherer, A. Weber, D. Vermeulen, A. Türler, K.E. Gregorich, R.A. Henderson, K.R. Czerwinski, B. Kadkhodayan, D.M. Lee, M. Nurmia, D. JF - Radiochimica Acta. 57 (1992) Y1 - 1992 SN - 0033-8230 SP - 93 EP - 100 ER - TY - JOUR A1 - Scherer, Ulrich W. A1 - Türler, A. A1 - Gäggeler, H. W. A1 - Gregorich, K. E. T1 - Gas phase chromatography of halides of elements 104 and 105 / A. Türler, H. W. Gäggeler, K. E. Gregorich, H. Barth, W. Brüchle, K. R. Czerwinski, M. K. Gober, N. J. Hannink, R. A. Henderson, D. C. Hoffman, D. T. Jost, C. D. Kacher, B. Kadkhodayan, J. Kova JF - Journal of Radioanalytical and Nuclear Chemistry. 160 (1992), H. 2 Y1 - 1992 SN - 0236-5731 SP - 327 EP - 339 ER - TY - JOUR A1 - Scherer, Ulrich W. A1 - Hör, G. A1 - Kranert, W. T. A1 - Maul, F. D. T1 - Gated Metabolic Positron Emission Tomography (GAPET) of Myocardium: 18F-FDG/PET to optimize Recognition of Myocardial Hibernation / G. Hör, W.T. Kranert, F.D. Maul, O. Schröder, A. Karimian-Tatriz, O. Geb, R.P. Baum, U.W. Scherer JF - Nuclear Medicine Communications. 19 (1998) Y1 - 1998 SN - 0143-3636 SP - 535 EP - 545 ER - TY - JOUR A1 - Dallas, Shannon A1 - Salphati, Laurent A1 - Gomez-Zepeda, David A1 - Wanek, Thomas A1 - Chen, Liangfu A1 - Chu, Xiaoyan A1 - Kunta, Jeevan A1 - Mezler, Mario A1 - Menet, Marie-Claude A1 - Chasseigneaux, Stephanie A1 - Declèves, Xavier A1 - Langer, Oliver A1 - Pierre, Esaie A1 - DiLoreto, Karen A1 - Hoft, Carolin A1 - Laplanche, Loic A1 - Pang, Jodie A1 - Pereira, Tony A1 - Andonian, Clara A1 - Simic, Damir A1 - Rode, Anja A1 - Yabut, Jocelyn A1 - Zhang, Xiaolin A1 - Scheer, Nico T1 - Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model JF - Molecular Pharmacology N2 - Breast cancer resistance protein (BCRP) is expressed in various tissues, such as the gut, liver, kidney and blood brain barrier (BBB), where it mediates the unidirectional transport of substrates to the apical/luminal side of polarized cells. Thereby BCRP acts as an efflux pump, mediating the elimination or restricting the entry of endogenous compounds or xenobiotics into tissues and it plays important roles in drug disposition, efficacy and safety. Bcrp knockout mice (Bcrp−/−) have been used widely to study the role of this transporter in limiting intestinal absorption and brain penetration of substrate compounds. Here we describe the first generation and characterization of a mouse line humanized for BCRP (hBCRP), in which the mouse coding sequence from the start to stop codon was replaced with the corresponding human genomic region, such that the human transporter is expressed under control of the murine Bcrp promoter. We demonstrate robust human and loss of mouse BCRP/Bcrp mRNA and protein expression in the hBCRP mice and the absence of major compensatory changes in the expression of other genes involved in drug metabolism and disposition. Pharmacokinetic and brain distribution studies with several BCRP probe substrates confirmed the functional activity of the human transporter in these mice. Furthermore, we provide practical examples for the use of hBCRP mice to study drug-drug interactions (DDIs). The hBCRP mouse is a promising model to study the in vivo role of human BCRP in limiting absorption and BBB penetration of substrate compounds and to investigate clinically relevant DDIs involving BCRP. Y1 - 2016 U6 - http://dx.doi.org/10.1124/mol.115.102079 SN - 1521-0111 VL - 89 IS - 5 SP - 492 EP - 504 PB - ASPET CY - Bethesda, Md. ER - TY - JOUR A1 - Scheer, Nico A1 - Balimane, Praveen A1 - Hayward, Michael D. A1 - Buechel, Sandra A1 - Kauselmann, Gunther A1 - Wolf, C. Roland T1 - Generation and Characterization of a Novel Multidrug Resistance Protein 2 Humanized Mouse Line JF - Drug Metabolism and Disposition N2 - The multidrug resistance protein (MRP) 2 is predominantly expressed in liver, intestine, and kidney, where it plays an important role in the excretion of a range of drugs and their metabolites or endogenous compounds into bile, feces, and urine. Mrp knockout [Mrp2(−/−)] mice have been used recently to study the role of MRP2 in drug disposition. Here, we describe the first generation and initial characterization of a mouse line humanized for MRP2 (huMRP2), which is nulled for the mouse Mrp2 gene and expresses the human transporter in the organs and cell types where MRP2 is normally expressed. Analysis of the mRNA expression for selected cytochrome P450 and transporter genes revealed no major changes in huMRP2 mice compared with wild-type controls. We show that human MRP2 is able to compensate functionally for the loss of the mouse transporter as demonstrated by comparable bilirubin levels in the humanized mice and wild-type controls, in contrast to the hyperbilirubinemia phenotype that is observed in MRP2(−/−) mice. The huMRP2 mouse provides a model to study the role of the human transporter in drug disposition and in assessing the in vivo consequences of inhibiting this transporter by compounds interacting with human MRP2. Y1 - 2012 U6 - http://dx.doi.org/10.1124/dmd.112.047605 SN - 1521-0111 VL - 40 IS - 11 SP - 2212 EP - 2218 PB - ASPET CY - Bethesda, Md. ER - TY - JOUR A1 - Scheer, Nico A1 - Kapelyukh, Yury A1 - Rode, Anja A1 - Buechel, Sandra A1 - Wolf, C. Roland T1 - Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines JF - Molecular Pharmacology N2 - Compared with rodents and many other animal species, the human cytochrome P450 (P450) Cyp2c gene cluster varies significantly in the multiplicity of functional genes and in the substrate specificity of its enzymes. As a consequence, the use of wild-type animal models to predict the role of human CYP2C enzymes in drug metabolism and drug-drug interactions is limited. Within the human CYP2C cluster CYP2C9 is of particular importance, because it is one of the most abundant P450 enzymes in human liver, and it is involved in the metabolism of a wide variety of important drugs and environmental chemicals. To investigate the in vivo functions of cytochrome P450 Cyp2c genes and to establish a model for studying the functions of CYP2C9 in vivo, we have generated a mouse model with a deletion of the murine Cyp2c gene cluster and a corresponding humanized model expressing CYP2C9 specifically in the liver. Despite the high number of functional genes in the mouse Cyp2c cluster and the reported roles of some of these proteins in different biological processes, mice deleted for Cyp2c genes were viable and fertile but showed certain phenotypic alterations in the liver. The expression of CYP2C9 in the liver also resulted in viable animals active in the metabolism and disposition of a number of CYP2C9 substrates. These mouse lines provide a powerful tool for studying the role of Cyp2c genes and of CYP2C9 in particular in drug disposition and as a factor in drug-drug interaction. Y1 - 2012 U6 - http://dx.doi.org/10.1124/mol.112.080036 SN - 1521-0111 VL - 82 IS - 6 SP - 1022 EP - 1029 PB - ASPET CY - Bethesda, Md. ER - TY - JOUR A1 - Scheer, Nico A1 - Snaith, Mike A1 - Wolf, C. Roland A1 - Seibler, Jost T1 - Generation and utility of genetically humanized mouse models JF - Drug Discovery Today Y1 - 2013 U6 - http://dx.doi.org/10.1016/j.drudis.2013.07.007 SN - 1359-6446 VL - Vol 18 IS - 23-24 SP - 1200 EP - 1211 PB - Elsevier CY - Amsterdam ER - TY - JOUR A1 - Lassonczyk, Beate A1 - Alaily, F. A1 - Huth, A. A1 - Gensior, A. T1 - Genesis of soils in the arid part of northeast Somalia / F. Alaily, B. Lassonczyk, A.Huth and A. Gensior JF - Berliner geowissenschaftliche Abhandlungen / Reihe A, Geologie und Paläontologie / hrsg. von d. Geowissenschaftlichen Instituten der Freien u. d. Technischen Universität Berlin. 120 A (1990) Y1 - 1990 SN - 0172-8784 SP - 695 EP - 711 ER - TY - JOUR A1 - Borgmeier, Claudia A1 - Bongaerts, Johannes A1 - Meinhardt, Friedhelm T1 - Genetic analysis of the Bacillus licheniformis degSU operon and the impact of regulatory mutations on protease production JF - Journal of biotechnology N2 - Disruption experiments targeted at the Bacillus licheniformis degSU operon and GFP-reporter analysis provided evidence for promoter activity immediately upstream of degU. pMutin mediated concomitant introduction of the degU32 allele – known to cause hypersecretion in Bacillus subtilis – resulted in a marked increase in protease activity. Application of 5-fluorouracil based counterselection through establishment of a phosphoribosyltransferase deficient Δupp strain eventually facilitated the marker-free introduction of degU32 leading to further protease enhancement achieving levels as for hypersecreting wild strains in which degU was overexpressed. Surprisingly, deletion of rapG – known to interfere with DegU DNA-binding in B. subtilis – did not enhance protease production neither in the wild type nor in the degU32 strain. The combination of degU32 and Δupp counterselection in the type strain is not only equally effective as in hypersecreting wild strains with respect to protease production but furthermore facilitates genetic strain improvement aiming at biological containment and effectiveness of biotechnological processes. KW - Marker-free mutagenesis KW - Extracellular enzymes KW - Uracil-phosphoribosyltransferase KW - Hypersecretion Y1 - 2012 U6 - http://dx.doi.org/10.1016/j.jbiotec.2012.02.011 SN - 1873-4863 (E-Journal); 0168-1656 (Print) VL - 159 IS - 1-2 SP - 12 EP - 20 PB - Elsevier CY - Amsterdam ER - TY - JOUR A1 - Deppe, Veronika Maria A1 - Klatte, Stephanie A1 - Bongaerts, Johannes A1 - Maurer, Karl-Heinz A1 - O'Connell, Timothy A1 - Meinhardt, Friedhelm T1 - Genetic control of Amadori product degradation in Bacillus subtilis via regulation of frlBONMD expression by FrlR JF - Applied and environmental microbiology Y1 - 2011 SN - 1098-5336 (E-Journal); 0003-6919 (Print); 0099-2240 (Print) VL - Vol. 77 IS - No. 9 SP - 2839 EP - 2846 PB - American Society of Mechanical Engineers (ASME) CY - New York ER - TY - JOUR A1 - Medlin, L. K. A1 - Lange, M. A1 - Baumann, Marcus T1 - Genetic differentiation among three colony-forming species of Phaeocystis : further evidence for the phylogeny of the Prymnesiophyta JF - Phycologia Y1 - 1994 SN - 0031-8884 VL - Vol. 33 IS - Iss. 3 SP - 199 EP - 212 ER - TY - CHAP A1 - Samuelsson, K. A1 - Scheer, Nico A1 - Wilson, I. A1 - Wolf, C.R. A1 - Henderson, C.J. ED - Chackalamannil, Samuel T1 - Genetically Humanized Animal Models T2 - Comprehensive Medicinal Chemistry III. 3rd Edition N2 - Genetically humanized mice for proteins involved in drug metabolism and toxicity and mice engrafted with human hepatocytes are emerging as promising in vivo models for improved prediction of the pharmacokinetic, drug–drug interaction, and safety characteristics of compounds in humans. This is an overview on the genetically humanized and chimeric liver-humanized mouse models, which are illustrated with examples of their utility in drug metabolism and toxicity studies. The models are compared to give guidance for selection of the most appropriate model by highlighting advantages and disadvantages to be carefully considered when used for studies in drug discovery and development. KW - Chimeric liver-humanized mice KW - Drug distribution KW - Drug metabolism KW - Toxicology KW - Knockout mice Y1 - 2017 SN - 978-0-12-803201-5 U6 - http://dx.doi.org/10.1016/B978-0-12-409547-2.12376-5 SP - 130 EP - 149 PB - Elsevier CY - Saint Louis ER - TY - JOUR A1 - Scheer, Nico A1 - Wolf, C. Roland T1 - Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications JF - Xenobiotica N2 - 1. Drug metabolizing enzymes and transporters play important roles in the absorption, metabolism, tissue distribution and excretion of various compounds and their metabolites and thus can significantly affect their efficacy and safety. Furthermore, they can be involved in drug–drug interactions which can result in adverse responses, life-threatening toxicity or impaired efficacy. Significant species differences in the interaction of compounds with drug metabolizing enzymes and transporters have been described. 2. In order to overcome the limitation of animal models in accurately predicting human responses, a large variety of mouse models humanized for drug metabolizing enzymes and to a lesser extent drug transporters have been created. 3. This review summarizes the literature describing these mouse models and their key applications in studying the role of drug metabolizing enzymes and transporters in drug bioavailability, tissue distribution, clearance and drug–drug interactions as well as in human metabolite testing and risk assessment. 4. Though such humanized mouse models have certain limitations, there is great potential for their use in basic research and for testing and development of new medicines. These limitations and future potentials will be discussed. KW - transporters KW - human metabolites KW - drug metabolising enzymes KW - drug–drug interactions KW - bioavailability Y1 - 2014 U6 - http://dx.doi.org/10.3109/00498254.2013.815831 SN - 1366-5928 VL - 44 IS - 2 SP - 96 EP - 108 PB - Taylor & Francis CY - Abingdon ER - TY - JOUR A1 - Waller, Mark P. A1 - Braun, Heiko A1 - Hojdis, Nils A1 - Bühl, Michael T1 - Geometries of Second-Row Transition-Metal Complexes from Density-Functional Theory JF - Journal of Chemical Theory and Computation Y1 - 2007 U6 - http://dx.doi.org/10.1021/ct700178y SN - 1549-9626 VL - 3 IS - 6 SP - 2234 EP - 2242 ER - TY - JOUR A1 - Kotter, Michael A1 - Hammon, Ulrich A1 - Riekert, Lothar T1 - Gewinnung niedriger Olefine aus Methanol bei partiellem Umsatz mit Rückführung / U. Hammon ; M. Kotter ; L. Riekert JF - Chemie - Ingenieur - Technik. 61 (1989), H. 2 Y1 - 1989 SN - 0009-286X N1 - ISSN der E-Ausg.: 1522-2640 SP - 151 EP - 152 ER - TY - JOUR A1 - Selmer, Thorsten A1 - Sommerlade, Hans-Jörg A1 - Ingendoh, Arnd A1 - Gieselmann, Volkmar T1 - Glycosylation and phosphorylation of arylsulfatase A / Sommerlade, Hans-Jörg. ; Selmer, Thomas. ; Ingendoh, Arnd ; Gieselmann, Volkmar ; Figura, Kurt von ; Neifer, Klaus ; Schmidt, Bernhard JF - Journal of Biological Chemistry. 269 (1994), H. 33 Y1 - 1994 SN - 1083-351X SP - 20977 EP - 20981 ER - TY - JOUR A1 - Sieker, Tim A1 - Neuner, Andreas A1 - Dimitrova, Darina A1 - Tippkötter, Nils A1 - Bart, Hans-Jörg A1 - Heinzle, Elmar A1 - Ulber, Roland T1 - Grassilage als Rohstoff für die chemische Industrie JF - Chemie Ingenieur Technik N2 - Grassilage stellt einen nachwachsenden Rohstoff mit großem Potenzial dar. Neben Cellulose und Hemicellulose enthält sie auch organische Säuren, insbesondere Milchsäure. In einem Bioraffinerie-Projekt wird die Milchsäure aus der Silage isoliert und mit gentechnisch optimierten Stämmen zu L-Lysin weiterverarbeitet. Die Lignocellulose wird hydrolysiert und zu Ethanol fermentiert. Ein besonderes Augenmerk liegt auf der Integration der unterschiedlichen Prozesse sowie der einzelnen Prozessschritte zu einem Gesamtprozess, der sämtliche Inhaltsstoffe der Silage verwertet. Y1 - 2010 U6 - http://dx.doi.org/10.1002/cite.201000088 SN - 1522-2640 VL - 82 IS - 8, Special Issue: Industrielle Nutzung nachwachsender Rohstoffe SP - 1153 EP - 1159 PB - Wiley-VCH CY - Weinheim ER -